

**Preliminary Amendment**

Page 9 of 11

Applicant(s): Michael S. KINCH et al.

Serial No.: 09/640,952

Filed: August 17, 2000

For: EPHA2 AS A DIAGNOSTIC TARGET FOR METASTATIC CANCER (As Amended)

- A3  
Conclude
84. A monoclonal antibody produced by hybridoma cell line D7.
85. An isolated monoclonal antibody produced by hybridoma cell line D7.
86. The antibody of claim 18 which is a monoclonal antibody.
87. An isolated antibody which specifically binds to an intracellular epitope of EphA2.
88. The isolated antibody of claim 87 which is a monoclonal antibody.
89. The method of claim 14 wherein the myeloma cells are Bcl-2-overexpressing.

**In the Specification**

Please amend the specification as follows:

At page 1, line 1, delete the title "ANTIBODIES AS A CANCER DIAGNOSTIC" and substitute therefor the new title –EPHA2 AS A DIAGNOSTIC TARGET FOR METASTATIC CANCER–.

At page 1, line 8, insert --

**Government Funding**

The present invention was made with government support under Grant No. DAMD 17-98-1-8146, awarded by Army Breast Cancer. The Government has certain rights in this invention.–

At page 1, line 12, delete "bond to an intracellular epitope of" and insert therefor –bind to–.

At page 2, line 24, delete "analogies" and insert therefor –analogues--

At page 5, line 22, delete "cites" and insert therefor –sites–.